193 related articles for article (PubMed ID: 21998480)
1. Time to refocus on HSV interventions for HIV prevention?
Tanton C; Abu-Raddad LJ; Weiss HA
J Infect Dis; 2011 Dec; 204(12):1822-6. PubMed ID: 21998480
[No Abstract] [Full Text] [Related]
2. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
3. Herpes treatment may limit HIV transmission and progression.
Wilkinson E
Lancet Infect Dis; 2007 Apr; 7(4):249. PubMed ID: 17419138
[No Abstract] [Full Text] [Related]
4. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
5. A missed point in deciphering the viral synergy between herpes simplex virus and HIV.
Lisco A; Vanpouille C; Margolis L
Lancet Infect Dis; 2009 Sep; 9(9):522-3. PubMed ID: 19695487
[No Abstract] [Full Text] [Related]
6. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
7. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
8. Use of antiviral drugs to prevent herpesvirus transmission.
Crumpacker CS
N Engl J Med; 2004 Jan; 350(1):67-8. PubMed ID: 14702430
[No Abstract] [Full Text] [Related]
9. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
[TBL] [Abstract][Full Text] [Related]
10. HSV therapy and HIV-1 reduction.
Martinez V; Caumes E
N Engl J Med; 2007 May; 356(22):2323; author reply 2324. PubMed ID: 17538093
[No Abstract] [Full Text] [Related]
11. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
13. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
[TBL] [Abstract][Full Text] [Related]
14. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus: a new era?
Van de Perre P; Nagot N
Lancet; 2012 Feb; 379(9816):598-9. PubMed ID: 22226046
[No Abstract] [Full Text] [Related]
16. HSV-2 suppression reduces HIV and HSV shedding.
Collins S
GMHC Treat Issues; 2005 Dec; 19(12):11. PubMed ID: 16909510
[No Abstract] [Full Text] [Related]
17. Short communication: T cell activation in HIV-1/herpes simplex virus-2-coinfected Kenyan women receiving valacyclovir.
Roxby AC; Liu AY; Drake AL; Kiarie JN; Richardson B; Lohman-Payne BL; John-Stewart GC; Wald A; De Rosa S; Farquhar C
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):94-8. PubMed ID: 22852760
[TBL] [Abstract][Full Text] [Related]
18. Trial shows HSV-2 suppression can reduce HIV shedding.
IAVI Rep; 2006; 10(1):20. PubMed ID: 16628770
[No Abstract] [Full Text] [Related]
19. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
20. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
